Rituxan copycat passes first pivotal test for Amgen, Allergan; Ironwood and biotech spinout name new boards
→ Amgen and their partners at Allergan say their pivotal study of a Rituxan knockoff came through with positive PK results for patients with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
